Latest / The Onco Life Podcast
FDA Approves Zongertinib (Hernexeos): First Oral HER2-Targeted Therapy for Advanced NSCLC
In this episode, we break down the FDA’s historic approval of zongertinib (Hernexeos), the first oral HER2-targeted therapy for advanced non-small cell lung cancer (NSCLC) with HER2 mutations. This milestone offers patients and clinicians a long-awaited, convenient, and effective treatment option.You’ll learn:Why have HER2-mutated NSCLC patients had limited options until nowHow zongertinib works differently from intravenous HER2 therapiesKey results from the Beamion LUNG-1 clinical trial, including a 71% response rateThe benefits of an oral, once-daily HER2 therapy for patients and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.